指南与共识重症综合管理与镇静镇痛呼吸衰竭与机械通气

COVID-19患者血栓预防:CHEST指南与专家小组报告简要更新

Thromboprophylaxis in Patients With COVID-19: A Brief Update to the CHEST Guideline and Expert Panel Report.
指南 / 共识 · Chest · 2022-02-12
一句话结论重症患者应接受标准血栓预防,中度病情且出血风险低者可能从治疗剂量肝素获益(CHEST指南更新)。

该更新聚焦住院COVID-19患者血栓预防的最佳策略,检索PubMed/MEDLINE,纳入8项随机对照试验和1项观察性研究,采用随机效应模型进行Meta分析,并基于GRADE证据到决策框架和改良Delphi法形成共识。指南分别针对急性(中度)病情住院患者和ICU重症患者给出预防建议,将原问题拆分为标准预防对比治疗(或升级剂量)预防、标准预防对比中间剂量预防。更新导致1条推荐改变、3条推荐因证据质量提高而升级。结论指出重症患者应接受标准血栓预防,中度病情且出血风险低者可能从治疗剂量肝素获益,两种场景均无中间剂量血栓预防的角色。

要点

  • 重症COVID-19患者应接受标准血栓预防(CHEST指南更新)。
  • 中度病情且出血风险低的COVID-19住院患者可能从治疗剂量肝素获益(CHEST指南更新)。
  • 在重症和中度病情两种场景下,中间剂量血栓预防均无角色(CHEST指南更新)。
  • 更新基于8项随机对照试验和1项观察性研究的Meta分析(随机效应模型)。
  • 更新导致1条推荐改变、3条推荐因证据质量提高而升级。

适用人群与场景

  • 住院的COVID-19患者,分为急性(中度)病情住院患者和ICU重症患者。
  • 中度病情患者中,出血风险低者可能从治疗剂量肝素获益。

处置流程与药物剂量

  • 重症COVID-19患者应接受标准血栓预防(CHEST指南更新)。
  • 中度病情COVID-19住院患者,若出血风险低,可能从治疗剂量肝素获益(CHEST指南更新)。
  • 在重症和中度病情两种场景下,中间剂量血栓预防均无角色(CHEST指南更新)。

研究设计与关键结果

  • 本更新纳入8项随机对照试验和1项观察性研究,采用随机效应模型进行Meta分析。
  • 专家组使用GRADE证据到决策框架生成摘要,并采用改良Delphi法达成共识。
  • 更新将原问题拆分为标准预防对比治疗(或升级剂量)预防、标准预防对比中间剂量预防,导致1条推荐改变、3条推荐因证据质量提高而升级。

证据类型、等级与局限

  • 证据类型:指南更新(基于8项随机对照试验和1项观察性研究的Meta分析)。
  • 证据分级体系:GRADE证据到决策框架。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对ICU重症COVID-19患者,实践为给予标准血栓预防,而非治疗剂量或中间剂量。
  • 对中度病情COVID-19住院患者,若出血风险低,可考虑治疗剂量肝素(作者认为可能获益)。
  • 两种场景下均不采用中间剂量血栓预防。

指南或共识出处

  • CHEST指南与专家小组报告:COVID-19患者血栓预防简要更新(CHEST)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients hospitalized with COVID-19 often exhibit markers of a hypercoagulable state and have an increased incidence of VTE. In response, CHEST issued rapid clinical guidance regarding prevention of VTE. Over the past 18 months the quality of the evidence has improved. We thus sought to incorporate this evidence and update our recommendations as necessary.

STUDY DESIGN AND METHODS: This update focuses on the optimal approach to thromboprophylaxis in hospitalized patients. The original questions were used to guide the search, using MEDLINE via PubMed. Eight randomized controlled trials and one observational study were included. Meta-analysis, using a random effects model, was performed. The panel created summaries using the GRADE Evidence-to-Decision framework. Updated guidance statements were drafted, and a modified Delphi approach was used to obtain consensus.

RESULTS: We provide separate guidance statements for VTE prevention for hospitalized patients with acute (moderate) illness and critically ill patients in the ICU. However, we divided each original question and resulting recommendation into two questions: standard prophylaxis vs therapeutic (or escalated dose) prophylaxis and standard prophylaxis vs intermediate dose prophylaxis. This led to a change in one recommendation, and an upgrading of three additional recommendations based upon higher quality evidence.

CONCLUSIONS: Advances in care for patients with COVID-19 have improved overall outcomes. Despite this, rates of VTE in these patients remain elevated. Critically ill patients should receive standard thromboprophylaxis for VTE, and moderately ill patients with a low bleeding risk might benefit from therapeutic heparin. We see no role for intermediate dose thromboprophylaxis in either setting.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Moores LK, Tritschler T, Brosnahan S, et al. Thromboprophylaxis in Patients With COVID-19: A Brief Update to the CHEST Guideline and Expert Panel Report. Chest. 2022. PMID: 35167861. doi:10.1016/j.chest.2022.02.006

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。